Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip Conference

Paul Vulto's Biography



Paul Vulto, Managing Director, MIMETAS

Paul Vulto is CEO and co-founder of MIMETAS. Under his guidance, MIMETAS developed into a multinational company with operations in Europe, US and Japan. MIMETAS currently works with the majority of top-50 pharma companies and counts over 85 co-workers. Paul is the inventor behind the OrganoPlate® platform and PhaseGuide technology of MIMETAS. Prior to founding MIMETAS, Paul worked for the high-tech company Silicon Biosystems in Bologna, the Institute for Microsystems Engineering (IMTEK) at the University of Freiburg and the Leiden Academic Centre for Drug Research, Leiden University. Paul holds a cum Laude masters degree in Electrical Engineering and a cum Laude PhD degree in Microsystems Engineering.

Paul Vulto Image

3D Co-cultures and Membrane-free Boundary Tissues for Enhanced Compound Screening

Thursday, 9 July 2015 at 11:30

Add to Calendar ▼2015-07-09 11:30:002015-07-09 12:30:00Europe/London3D Co-cultures and Membrane-free Boundary Tissues for Enhanced Compound ScreeningSELECTBIOenquiries@selectbiosciences.com

The challenge in creating better biomimetic models lies in capturing the 3D morphology, heterogeneity and boundary aspects of tissues. Our platform allows for a stratified layering of extracellular matrix gels optionally alternated with medium perfusion channels. Multiple lanes could be defined with the help of capillary pressure barriers called phaseguides. Clusters of cells are grown in the ECM matrix to provide a natural 3D tissue environment. Monolayer of cells deposited against the ECM matrix form boundary tissues that typically develop into tubuli. The 3D environment enables long term culture (> two months) and differentiation of cell clusters. iPS neurons were grown over two months and showed both induced and spontaneous electrophysiological activity as shown by in chip transfected calcium reporters. Lgr5+ small intestinal organoids developed crypt-villi morphology that is typically associated with gut epithelium. Endothele and epithele vessels were co-cultured with fibroblasts and pericytes to capture the heterogeneity of the kidney. Our platform is based on a microtiter plate footprint, harboring 96 culture chambers. Thin 175µm glass optical access renders the system fully compatible with both fluorescent and luminescent readout. Our platform is an important step in making Organ-on-a-Chip available for high throughput compound screening.


Add to Calendar ▼2015-07-08 00:00:002015-07-09 00:00:00Europe/LondonOrgan-on-a-Chip ConferenceSELECTBIOenquiries@selectbiosciences.com